PASI score

パッシースコア

WordNet

1. write a musical score for
2. a slight surface cut (especially a notch that is made to keep a tally) (同)scotch
3. a number that expresses the accomplishment of a team or an individual in a game or contest; "the score was 7 to 0"
4. an amount due (as at a restaurant or bar); "add it to my score and Ill settle later"
5. the act of scoring in a game or sport; "the winning score came with less than a minute left to play"
6. grounds; "dont do it on my account"; "the paper was rejected on account of its length"; "he tried to blame the victim but his success on that score was doubtful" (同)account
7. a written form of a musical composition; parts for different instruments appear on separate staves on large pages; "he studied the score of the sonata" (同)musical score
8. a set of twenty members; "a score were sent out but only one returned"
9. the facts about an actual situation; "he didnt know the score"
10. gain points in a game; "The home team scored many times"; "He hit a home run"; "He hit .300 in the past season" (同)hit, tally, rack_up
11. make underscoring marks (同)mark
12. make small marks into the surface of; "score the clay before firing it" (同)nock, mark
13. get a certain number or letter indicating quality or performance; "She scored high on the SAT"; "He scored a 200"

PrepTutorEJDIC

1. (ゲーム・競技の)『スコア』,得点記録 / (ゲーム・競技の)『得点』 / (試験の)点数,評点 / 《おもに文》20[の単位] / 《複数形で》多数(の…)《+『of』+『名』》 / 《まれ》勘定,借金 / 《単数形で》理由,根拠,原因 / (また『score mark』)刻み目,線,印 / 総譜,楽譜 / (ゲーム・競技で)〈点数〉‘を'『得点する』 / 〈競技〉‘の'得点を記録する / 〈得点〉‘を'〈人〉‘に'与える《+『名』〈人〉+『名』〈得点〉=+『名』〈得点〉+『to』(『for』)+『名』〈人〉》 / 〈試験〉‘を'採点する;(試験で)…‘の'点をとる《+『名』+『on』+『名』》 / (…で)…‘に'刻み目(印)をつける,線をひく《+『名』+『with』+『名』》 / 《米話》…‘を'こきおろす,酷評する / 《通例受動態で》(…のために)〈音楽〉‘を'作曲(編曲)する《+『for』+『名』》 / (ゲーム・競技で)『得点する』 / 優勢となる,成功する / 《俗》〈男が〉(女を)くどき落とす《+『with』+『名』》 / 《俗》麻薬を売う
2. personal assistant個人秘書 / public address [system]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 乾癬性関節炎の治療 treatment of psoriatic arthritis
• 2. 自家造血幹細胞移植の適格性判定 determining eligibility for autologous hematopoietic cell transplantation
• 3. Risk assessment of patients with chemotherapy-induced neutropenia
• 4. 慢性肝疾患に対する組織学的スコアリングシステム histologic scoring systems for chronic liver disease
• 5. 下肢深部静脈血栓症が疑われた場合の診断 diagnosis of suspected deep vein thrombosis of the lower extremity

English Journal

• Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

• Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.SourceDepartment of Dermatology, Oregon Health and Science University, 2565 NW Lovejoy #200, Portland, OR, U.S.A. Department of Dermatology, University of Iceland, Reykjavik, Iceland Department of Dermatology, Venereology and Allergology, JW Goethe University, Frankfurt, Germany Department for Dermatology, CHU Nice-Hospital Archet 2, Nice, France Paul Sabatier University, CNRS5165-INSERM1056, Toulouse, France Department of Dermatology, Johannes Gutenberg University, Mainz, Germany Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan Novartis Pharma AG, Basel, Switzerland.
• The British journal of dermatology.Br J Dermatol.2013 Feb;168(2):402-411. doi: 10.1111/bjd.12112.
• Background  Interleukin (IL)-17A has major proinflammatory activity in psoriatic lesional skin. Objectives  To assess the efficacy and safety of secukinumab, a fully human IgG1κ monoclonal anti-IL-17A antibody, in moderate-to-severe plaque psoriasis in a phase II regimen-finding study. Methods�
• PMID 23362969

• Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

• Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.SourceProbity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada Division of Dermatology, Dalhousie University, Halifax, NS, Canada Department of Dermatology, University of Iceland, Reykjavik, Iceland Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan Allergy, Asthma and Dermatology Research Center, Lake Oswego, OR, U.S.A. Department of Dermatology, East Tallinn Central Hospital, Tallinn, Estonia Novartis Pharma AG, Basel, Switzerland.
• The British journal of dermatology.Br J Dermatol.2013 Feb;168(2):412-421. doi: 10.1111/bjd.12110. Epub 2013 Jan 18.
• Background  Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long-term safety. Interleukin (IL)-17A is believed to be an important effector cytokine i
• PMID 23106107

• An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.

• Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ.SourcePsoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany Aarhus University Hospital, Aarhus, Denmark Dermatologikum Hamburg, Hamburg, Germany Dermatology Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, U.K. Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-3500, U.S.A.
• The British journal of dermatology.Br J Dermatol.2013 Feb;168(2):374-80. doi: 10.1111/j.1365-2133.2012.11214.x. Epub 2012 Dec 13.
• Background  The European Consensus Programme (ECP) established pan-European consensus definitions of psoriasis disease severity and treatment goals among 19 psoriasis experts from European nations. Objectives  To use the ECP treatment goals to retrospectively assess adalimumab efficacy in patien
• PMID 22880843

Japanese Journal

• Factors Associated with Increased Aqueous Flare in Psoriasis

• OKAMOTO Fumiki,UMEBAYASI Yoshihiro,OHTSUKA Fujio,HOMMURA Sachiko
• Japanese journal of ophthalmology 45(2), 172-176, 2001-03-01
• NAID 10013888305

• 尋常性乾癬に対する抗甲状腺剤内服療法 (群馬大学法) の有用性について

• 安部 正敏,大西 一徳,青山 久美,田村 敦志,長谷川 道子,石川 治,村上 正巳
• 日本皮膚科学会雑誌 110(10), 1549-1556, 2000-09-20
• NAID 10007724740

Related Links

• 皮膚とアレルギーの情報サイト かゆみナビ - 診断（2）：PASIスコア

尋常性乾癬とは？乾癬の症状、症例写真、原因、治療、日常生活上の注意点などを 紹介。協和発酵キリンの皮膚とアレルギーの情報サイト。

Related Pictures

---

★リンクテーブル★

リンク元	「パッシースコア」
関連記事	「PA」「PAS」「score」「scoring」

「パッシースコア」

　　[★]

英

PASI score

同

PASIスコア

概念

• psoriasis area and severity indexの略。乾癬の重症度判定のために広く用いられている。病変の重症度と面積で判定し、0～72のスコアが与えられる。

参考

• 1. wiki en

• http://en.wikipedia.org/wiki/Psoriasis_Area_and_Severity_Index

• 2. 写真入りの重症度解説

http://www.dermnet.org.nz/scaly/pasi.html

• 3. 記入用紙

https://www.health.gov.bc.ca/exforms/pharmacare/5379fil.pdf

• 4. 記入用紙

http://www.medicareaustralia.gov.au/provider/pbs/drugs1/files/ma_4178_PASI_calculation_and_whole_body_diagram.pdf

• 5. 記入用紙

http://www.medicareaustralia.gov.au/provider/pbs/drugs1/files/4177-pasi-calculation-and-body-diagram.pdf

「PA」

　　[★]

• 肺動脈弁閉鎖症 pulmonary atresia
• 肺動脈 pulmonary artery、肺動脈幹
• 原発性アルドステロン症 primary aldosteronism

• 微生物学：粒子凝集法(particle agglutination test)
• 薬理学：

　

「PAS」

　　[★]

• periodic acid-Schiff reagent
• PAS染色
• パラアミノサリチル酸 p-aminosalicylic acid para-amino salicylic acid

同

para-amino salicylic acid

「score」

　　[★]

• n.

• スコア

• v.

• 点数化する、スコア化する

関

scoring

　 　 　 　 　 　 　 　 　 　 　 　 　 　

「scoring」

　　[★]

• n.

• スコアリング、点数化、スコア付け

関

score